GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
pharmaphorum3d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Investing3d
Leerink upgrades Gilead stock on promising HIV outlook and oncology readouts
The analyst at Leerink expressed agreement with the market's positive reception to the drug's prospects for HIV pre-exposure prophylaxis ... as sales of Biktarvy, its leading HIV drug, are ...
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...